What can economics add to health technology assessment? Please not just another cost-effectiveness analysis!

John F.P. Bridges

Research output: Contribution to journalReview article


Evidence-based medicine is not only important for clinical practice, but national governments have embraced it through health technology assessment (HTA). HTA combines data from randomized controlled trials and observational studies with an economic component (among other issues). HTA, however, is not taking full advantage of economics. This review presents five areas in which economics may improve not only HTA, but the randomized controlled trials methods that underpin it. HTA needs to live up to its original agenda of being an interdisciplinary field and draw methods not just from biostatistics, but from a range of disciplines, including economics. By focusing only on cost-effectiveness analysis, however, we go nowhere near to fulfilling this potential.

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Issue number1
StatePublished - Feb 1 2006



  • Cost-effectiveness analysis
  • Evidence based medicine
  • Health technology assessment
  • Randomized controlled trials

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this